Zunich-Kaye syndrome
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Zunich-Kaye syndrome Classification and external resources | |
| ICD-9 | xxx |
|---|---|
| OMIM | 280000 |
| DiseasesDB | 32624 |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Zunich-Kaye syndrome, also known as Zunich neuroectodermal syndrome, is a rare congenital ichthyosis first described in 1983.[1] It is also referred to as CHIME syndrome, after its main symptoms (colobomas, heart defects, ichthyosiform dermatosis, mental retardation, and either ear defects or epilepsy).[1] It is a congenital[1] syndrome with only a few cases studied and published.[1]
Symptoms
Associated symptoms range from things such as colobomas of the eyes, heart defects, ichthyosiform dermatosis, mental retardation, and ear abnormalities. Further symptoms that may be suggested include characteristic facies, hearing loss, and cleft palate.
Genetics
Zunich-Kay syndrome is considered to have an autosomal recessive inheritance pattern. This means the defective gene is located on an autosome, and two copies of the gene, one from each parent, are required to inherit the disorder. The parents of an individual with autosomal recessive disorder both carry one copy of the defective gene, but usually do not have the disorder.
Treatment
Treatment with isotretinoin may induce substantial resolution of skin lesions, but the risk of secondary infection remains.[1]
References
Bibliography
- Schnur RE, Greenbaum BH, Heymann WR, Christensen K, Buck AS, Reid CS (1997). "<24::AID-AJMG5>3.0.CO;2-V Acute lymphoblastic leukemia in a child with the CHIME neuroectodermal dysplasia syndrome". Am. J. Med. Genet. 72 (1): 24–9. PMID 9295069.
- Shashi V, Zunich J, Kelly TE, Fryburg JS (1995). "Neuroectodermal (CHIME) syndrome: an additional case with long term follow up of all reported cases". J. Med. Genet. 32 (6): 465–9. PMID 7666399.
- Zunich J, Esterly NB, Holbrook KA, Kaye CI (1985). "Congenital migratory ichthyosiform dermatosis with neurologic and ophthalmologic abnormalities". Arch Dermatol 121 (9): 1149–56. PMID 4037840.
- Zunich J, Esterly NB, Kaye CI (1988). "Autosomal recessive transmission of neuroectodermal syndrome". Arch Dermatol 124 (8): 1188–9. PMID 3041916.
- Zunich J, Kaye CI (1984). "Additional case report of new neuroectodermal syndrome". Am. J. Med. Genet. 17 (3): 707–10. doi:10.1002/ajmg.1320170324. PMID 6711621.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
